Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency

S. Gonzalez, J. D. Windram, T. Sathyapalan, Z. Javed, A. L. Clark, Stephen Atkin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Epidemiological studies suggest that adult-onset growth hormone deficiency (AGHD) might increase the risk of death from cardiovascular causes. Methods: This was a 6-month double-blind, placebo-controlled, randomised, cross-over trial followed by a 6-month open-label phase. Seventeen patients with AGHD received either recombinant human growth hormone (rGH) (0.4 mg injection daily) or placebo for 12 weeks, underwent washout for 2 weeks, and were then crossed over to the alternative treatment for a further 12 weeks. Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase (12 months). The results were compared with those of 16 age- and sex-matched control subjects. Results: At baseline, patients with AGHD had a significantly higher systolic blood pressure, ejection fraction, and left ventricular mass than the control group, even when corrected for body surface area. Treatment with rGH normalised the insulin-like growth factor 1 concentration without an effect on exercise capacity, cardiac structure, or cardiac function. Conclusion: Administration of rGH therapy for 6 to 9 months failed to normalise the functional and structural cardiac differences observed in patients with AGHD when compared with a control group.

Original languageEnglish
Pages (from-to)1708-1719
Number of pages12
JournalJournal of International Medical Research
Volume45
Issue number6
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Human Growth Hormone
Growth Hormone
Exercise
Echocardiography
Blood pressure
Somatomedins
Magnetic resonance
Labels
Placebos
Control Groups
Imaging techniques
Body Surface Area
Testing
Stroke Volume
Cross-Over Studies
Epidemiologic Studies
Cause of Death
Therapeutics
Magnetic Resonance Imaging
Blood Pressure

Keywords

  • adult-onset growth hormone deficiency
  • cardiac function
  • cardiac magnetic resonance imaging
  • cardiac structure
  • exercise capacity
  • Growth hormone
  • hypopituitarism

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency. / Gonzalez, S.; Windram, J. D.; Sathyapalan, T.; Javed, Z.; Clark, A. L.; Atkin, Stephen.

In: Journal of International Medical Research, Vol. 45, No. 6, 01.12.2017, p. 1708-1719.

Research output: Contribution to journalArticle

@article{649a42209ff24542b806dd95f0170f69,
title = "Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency",
abstract = "Objective: Epidemiological studies suggest that adult-onset growth hormone deficiency (AGHD) might increase the risk of death from cardiovascular causes. Methods: This was a 6-month double-blind, placebo-controlled, randomised, cross-over trial followed by a 6-month open-label phase. Seventeen patients with AGHD received either recombinant human growth hormone (rGH) (0.4 mg injection daily) or placebo for 12 weeks, underwent washout for 2 weeks, and were then crossed over to the alternative treatment for a further 12 weeks. Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase (12 months). The results were compared with those of 16 age- and sex-matched control subjects. Results: At baseline, patients with AGHD had a significantly higher systolic blood pressure, ejection fraction, and left ventricular mass than the control group, even when corrected for body surface area. Treatment with rGH normalised the insulin-like growth factor 1 concentration without an effect on exercise capacity, cardiac structure, or cardiac function. Conclusion: Administration of rGH therapy for 6 to 9 months failed to normalise the functional and structural cardiac differences observed in patients with AGHD when compared with a control group.",
keywords = "adult-onset growth hormone deficiency, cardiac function, cardiac magnetic resonance imaging, cardiac structure, exercise capacity, Growth hormone, hypopituitarism",
author = "S. Gonzalez and Windram, {J. D.} and T. Sathyapalan and Z. Javed and Clark, {A. L.} and Stephen Atkin",
year = "2017",
month = "12",
day = "1",
doi = "10.1177/0300060517723798",
language = "English",
volume = "45",
pages = "1708--1719",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "6",

}

TY - JOUR

T1 - Effects of human recombinant growth hormone on exercise capacity, cardiac structure, and cardiac function in patients with adult-onset growth hormone deficiency

AU - Gonzalez, S.

AU - Windram, J. D.

AU - Sathyapalan, T.

AU - Javed, Z.

AU - Clark, A. L.

AU - Atkin, Stephen

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objective: Epidemiological studies suggest that adult-onset growth hormone deficiency (AGHD) might increase the risk of death from cardiovascular causes. Methods: This was a 6-month double-blind, placebo-controlled, randomised, cross-over trial followed by a 6-month open-label phase. Seventeen patients with AGHD received either recombinant human growth hormone (rGH) (0.4 mg injection daily) or placebo for 12 weeks, underwent washout for 2 weeks, and were then crossed over to the alternative treatment for a further 12 weeks. Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase (12 months). The results were compared with those of 16 age- and sex-matched control subjects. Results: At baseline, patients with AGHD had a significantly higher systolic blood pressure, ejection fraction, and left ventricular mass than the control group, even when corrected for body surface area. Treatment with rGH normalised the insulin-like growth factor 1 concentration without an effect on exercise capacity, cardiac structure, or cardiac function. Conclusion: Administration of rGH therapy for 6 to 9 months failed to normalise the functional and structural cardiac differences observed in patients with AGHD when compared with a control group.

AB - Objective: Epidemiological studies suggest that adult-onset growth hormone deficiency (AGHD) might increase the risk of death from cardiovascular causes. Methods: This was a 6-month double-blind, placebo-controlled, randomised, cross-over trial followed by a 6-month open-label phase. Seventeen patients with AGHD received either recombinant human growth hormone (rGH) (0.4 mg injection daily) or placebo for 12 weeks, underwent washout for 2 weeks, and were then crossed over to the alternative treatment for a further 12 weeks. Cardiac magnetic resonance imaging, echocardiography, and cardiopulmonary exercise testing were performed at baseline, 12 weeks, 26 weeks, and the end of the open phase (12 months). The results were compared with those of 16 age- and sex-matched control subjects. Results: At baseline, patients with AGHD had a significantly higher systolic blood pressure, ejection fraction, and left ventricular mass than the control group, even when corrected for body surface area. Treatment with rGH normalised the insulin-like growth factor 1 concentration without an effect on exercise capacity, cardiac structure, or cardiac function. Conclusion: Administration of rGH therapy for 6 to 9 months failed to normalise the functional and structural cardiac differences observed in patients with AGHD when compared with a control group.

KW - adult-onset growth hormone deficiency

KW - cardiac function

KW - cardiac magnetic resonance imaging

KW - cardiac structure

KW - exercise capacity

KW - Growth hormone

KW - hypopituitarism

UR - http://www.scopus.com/inward/record.url?scp=85038563365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038563365&partnerID=8YFLogxK

U2 - 10.1177/0300060517723798

DO - 10.1177/0300060517723798

M3 - Article

VL - 45

SP - 1708

EP - 1719

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 6

ER -